STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses (EVO ICL™) for vision correction, today announced that management...
5 Must-Read Analyst Questions From STAAR Surgical’s Q1 Earnings Call
1 Surging Stock Worth Your Attention and 2 We Ignore
STAA Q1 Deep Dive: China Momentum, Cost Discipline, and Stabilized Inventory Drive Turnaround
STAAR Surgical (NASDAQ:STAA) said its first quarter of 2026 marked a sharp rebound in sales and profitability, driven by strong demand in China, continued growth in the U.S. and tighter cost controls following...
STAAR Surgical (NASDAQ:STAA) Beats Expectations in Strong Q1 CY2026, Stock Jumps 18.3%
Net Sales of $93.5 million, highest first quarter Net Sales in Company’s history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 ...
Barchart Research What to Expect from STAA Earnings STAA Generated May 12, 2026 Current Price $28.18 EPS Estimate $$-0.03 Consensus Rating Hold Average Move 7.15% STAAR Surgical's China Inventory Restock...
Earnings To Watch: STAAR Surgical (STAA) Reports Q1 Results Tomorrow